Jump to content
SCLERO.ORG
Sclero Forums

Search the Community

Showing results for tags 'ra treatments'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 22 results

  1. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Among RA patients, a small statistically significant increase in developing cancer was observed for abatacept exposure. Seminars in Arthritis and Rheumatism, 09/03/2020. (Also see Biologic Agents and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Comparative Persistence of Methotrexate (MTX) and Tumor Necrosis Factor Inhibitors (TNFi) in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Concomitant use of MTX with a TNFi, however, is associated with improved TNFi persistence in all 3 diseases. PubMed, J Rheumatol, 2020 Jun 1;47(6):826-834. (Also see Treatments for Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis, Ankylosing Spondylitis and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles
  3. Radioscapholunate arthrodesis versus radiolunate arthrodesis in rheumatoid wrist surgery: clinical and radiographic outcomes. Our results have shown that radiolunate arthrodesis remains a reliable surgical procedure for advanced rheumatoid wrist. PubMed, Hand Surg Rehabil, 04/22/2020. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Implication of baseline levels and early changes of C-reactive protein (CRP) for subsequent clinical outcomes of patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). Baseline CRP appears to have a positive association with reaching the therapeutic target on TCZ treatment. PubMed, Ann rheumatologist Dis, 05/05/2020. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Clinical and Structural Efficacy of Hydroxychloroquine (HCQ) in Rheumatoid Arthritis (RA): A Systematic Review. Combining HCQ with other DMARDs could provide some clinical improvement in patients with RA. PubMed, Arthritis Care Res (Hoboken), 2020 Jan;72(1):36-40. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Effects of Sarilumab on Rheumatoid Arthritis (RA) as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease (RAID) Scale. Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients' lives to a greater extent than placebo + csDMARD or adalimumab monotherapy. PubMed, J Rheumatol, 2019 Oct;46(10):1259-1267. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Emerging therapies in rheumatoid arthritis (RA): focus on monoclonal antibodies. Advances in the treatment of RA are attributed to several aspects such as new classification criteria as well as better understanding of the pathogenesis of RA. PubMed, F1000Res, 2019 Aug 30;8. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. Our results suggest the concept that IL-1 inhibition may be considered a targeted treatment for RA and T2D. PubMed, PLoS Med, 2019 Sep 12;16(9):e1002901. (Also see Treatments for Rheumatoid Arthritis and Treatments for Diabetes) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Tocilizumab and the Risk of Cardiovascular Disease (CVD): Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis (RA) Patients. Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA. PubMed, Arthritis Care Res (Hoboken), 2019 Aug;71(8):1004-1018. (Also see Treatments for Rheumatoid Arthritis and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. More research is needed on tapering biologics, and should include studies of patient perspectives as well as health economic evaluations. PubMed, Musculoskeletal Care, 05/30/2019. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Intensive management for moderate rheumatoid arthritis: a qualitative study of patients' and practitioners' views. Some practitioners applied motivational interviewing techniques during standard care appointments and they would like the opportunity to address lifestyle issues with patients. PubMed, BMC Rheumatol, 2019 Mar 28;3:12. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Association betweenc and inflammation in patients with rheumatoid arthritis (RA) receiving biologic therapy. Elevated autophagy with significant correlation to inflammation suggests the involvement of autophagy in RA pathogenesis. PubMed, Arthritis Res Ther, 2018 Dec 5;20(1):268. (Also see Treatments for Rheumatoid Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. The effects of methotrexate (MTX) and hydroxychloroquine (HCQ) combination therapy vs methotrexate monotherapy in early rheumatoid arthritis (RA) patients. In contrast to indirect comparison review data, MTX–HCQ seems somewhat more effective after 6 months than MTX monotherapy in early RA patients. Rheumatology, 09/06/2018. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Long–term patient reported outcomes of elbow, wrist and hand surgery for rheumatoid arthritis (RA). Our original patient–reported outcome assessment tool revealed that elbow, wrist and hand surgery provided long–lasting benefits in RA patients and pain relief was the most favorable effect. PubMed, Int J rheumatologist Dis, 09/05/2018. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis. Findings suggested a relationship between the addition of adalimumab at 6 months after methotrexate failure and improved outcomes. PubMed, Ann rheumatologist Dis, 08/03/2018. (Also see Treatments for Rheumatoid Arthritis and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Predictors of Treatment Response in Rheumatoid Arthritis. This review article discusses the approaches used to identify theranostic biomarkers and to present an overview of currently available biomarkers and of their performance. PubMed, Joint Bone Spine, 07/04/2018. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. Ability of disease–modifying antirheumatic drugs to prevent or delay rheumatoid arthritis (RA) onset: a systematic literature review and meta–analysis (MA). This MA demonstrates that early therapeutic intervention may significantly reduce the risk of RA onset in this very first phase of the disease. PubMed, Ann rheumatologist Dis, 06/08/2018. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. Resveratrol (RSV) as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. It was found that the clinical markers and the disease activity score assessment for 28 joints were significantly lowered in the RSV–treated group. PubMed, Clin Rheumatol, 04/03/2018. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Safety and efficacy of alternate–day corticosteroid treatment (QOD CS) as adjunctive therapy for rheumatoid arthritis (RA) : a comparative study. QOD CS treatment leads to a lower infection rate and less CS dependence than does daily treatment and both RA treatments are equally effective. PubMed, Clin Rheumatol, 03/26/2018. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  20. Residual disease activity (RDA) in rheumatoid arthritis (RA) patients treated with subcutaneous biologic drugs that achieved remission or low disease activity (LDA). RDA in RA was present even in patients with remission or LDA, especially for the patient's reported outcome and impaired function was also present in a significantly rate of patients. PubMed, Clin Rheumatol, 02/21/2018. (Also see Treatments for Rheumatoid Arthritis and Biologic Agents) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related arti
  21. The risk of malignancy and its incidence in early rheumatoid arthritis (RA) patients treated with biologic DMARDs. In early RA patients, bDMARD use decreases the overall risk of developing malignancies; however, it does not affect the risk of developing hematologic malignancies. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):277. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  22. Dosing down and then discontinuing biologic therapy (bDMARD) in rheumatoid arthritis (RA): a review of the literature. In patients who have achieved low disease activity or remission, down–titration and discontinuation of bDMARD therapy may be attempted, with careful monitoring. PubMed, Int J rheumatologist Dis, 12/04/2017. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...